Grasustek®
ACTIVE PRINCIPLE:
pegfilgrastim
INDICATION:
neutropenia
DATE:
26/04/2019
STATUS:
Authorized
Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE:
pegfilgrastim
INDICATION:
neutropenia
DATE:
26/04/2019
STATUS:
Authorized
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.